18 June 2009: Innovation Norway has today granted NorDiag a new loan of NOK 6 million. The loan is related to development of applications for the "Bullet" and "Arrow" instruments. A condition for receiving the loan is that the company itself finances 50 per cent of the actual projects. Including this loan, NorDiag has a total of NOK 10 million in loan from Innovation Norway.

Contact:            
CFO Tone Kvåle,
phone +47 915 19576.

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for use in diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis, MRSA and DNA from stool. Applications for respiratory pathogens and viruses are under development. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Stockholm - Sweden and West Chester (PA) - USA. The group has 31 man years. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Read the notice in Norwegian here